Abstract
Over the 2 years covered here, there has been one clinical study in which a normal alpha-1 antitrypsin (AAT) gene was delivered to the nasal epithelium of AAT-deficient subjects using plasmid–liposome complexes; a second study using an adeno-associated vector should begin soon. Although progress in clinical studies has been slow, advances in both viral and nonviral vector designs show considerable promise. Strategies that combine liposome technology with imaginative vector design may permit long-term expression of a normal transgene that is sufficient to achieve therapeutic serum AAT concentrations. While reproducing the normal physiology by targeting normal AAT gene expression to the liver is logical, local expression in lung cells may be less demanding of the technology and offers therapeutic benefits that are produced neither by AAT protein therapy nor by AAT gene therapy targeted to the liver. Developing technologies may permit direct correction of the mutant AAT gene using innovative approaches to in vivo gene repair.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Flotte TR . Recombinant adeno-associated virus gene therapy for cystic fibrosis and [alpha]1-antitrypsin deficiency. Chest 2002; 121: 98S–102S.
http://www.alphaone.org/research/clinical_trials/Gene_Therapy_Trials.htm. 2002.
Brigham KL et al. Transfection of nasal mucosa with a normal alpha-1 antitrypsin (AAT) gene in AAT deficient subjects: comparison with protein therapy. Human Gene Therapy 2000; 11: 1023–1032.
Albelda SM, Wiewrodt R, Zuckerman JB . Gene therapy for lung disease: hype or hope? Ann Int Med 2000; 132: 649–660.
Loser P, Hillgenberg M, Arnold W, Both GW, Hofmann C . Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle. Gene Ther 2000; 7: 1491–1498.
Yotdna P et al. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 2002; 5: 233–241.
Song JE et al. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2001; 8: 1299–1306.
Stoll SM et al. Epstein-Barr virus/human vector provides high-level long-term expression of α1-antitrypsin in mice. Mol Ther 2001; 4: 122–129.
Chen Z-Y et al. Linesa Dnas concatemerize in vivo and result in sustained transgene expression in mouse liver. Mol Ther 2001; 3: 403–410.
Dasi F, Benet M, Crespo A, Alino SF . Asialofetuin liposome-mediated human α1- antitrypsin gene transfer in vivo results in stationary long-term gene expression. J Mol Med 2001; 79: 205–212.
Metz R et al. Mode of action of RNA/DNA oligonucleotides: progress in the development of gene repair as a therapy for [alpha]1-antitrypsin deficiency. Chest 2002; 121: 91S–97S.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stecenko, A., Brigham, K. Gene Therapy Progress and Prospects: Alpha-1 antitrypsin. Gene Ther 10, 95–99 (2003). https://doi.org/10.1038/sj.gt.3301947
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301947
Keywords
This article is cited by
-
Minicircle DNA Vectors Achieve Sustained Expression Reflected by Active Chromatin and Transcriptional Level
Molecular Therapy (2013)
-
Recombinant AAV Serotype and Capsid Mutant Comparison for Pulmonary Gene Transfer of α-1-Antitrypsin Using Invasive and Noninvasive Delivery
Molecular Therapy (2009)
-
Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use
Amino Acids (2006)
-
Genome–environment interactions in the molecular pathogenesis of dilated cardiomyopathy
Journal of Molecular Medicine (2005)